GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40698)

  • GC81867 structure
    GC81867Ac-ETDK(myr)-AMC acetate
    Purity: >98.00%

    Ac-ETDK(myr)-AMC acetate is a DLAT-derived ε-N-myristoyllysine peptide substrate for fatty-acid deacylase HDAC11, used in fluorescence-based HDAC11 activity assays.

  • GC81868 structure
    GC81868Acetyl-pepstatin ammonium
    Purity: >98.00%

    Acetyl-pepstatin ammonium is an aspartic protease ( PRs ) inhibitor that targets HIV-1 protease and XMRV protease with K i values of 13 nM and 712 nM, respectively.

  • GC81869 structure
    GC81869APP669-711 acetate
    Purity: >98.00%

    APP669-711 acetate is an N-terminally extended amyloid β peptide ( Aβ (-3)-40) that forms amyloid fibrils and co-deposits with Aβ in brain plaques, and also serves as a plasma biomarker for assessing brain Aβ load.

  • GC81870 structure
    GC81870Bethanidine hydriodide
    CAS: 2863-34-5
    Purity: >98.00%

    Bethanidine hydriodide is an orally active antihypertensive agent and adrenergic neuron blocker.

  • GC81871 structure
    GC81871CAP 6 m7G(LNA)(5')ppp(5')(2'OMeA)pG trisodium solution (100 mM ± 3 mM)
    Purity: >98.00%

    CAP 6 m7G(LNA)(5')ppp(5')(2'OMeA)pG trisodium solution (100 mM ± 3 mM) is a monomeric raw material that can be used for nucleic acid synthesis.

  • GC81872 structure
    GC81872CPTH2-d₄
    Purity: >98.00%

    CPTH2 -d 4 is the deuterated-labeled CPTH2.

  • GC81873 structure
    GC81873Ciprofloxacin hydrochloride
    CAS: 86483-48-9
    Purity: >98.00%

    Ciprofloxacin hydrochloride (Bay-09867 hydrochloride) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent.

  • GC81875 structure
    GC81875Histone H3 (1-25), amide acetate
    Purity: >98.00%

    Histone H3 (1-25), amide acetate is a synthetic N-terminal tail peptide derived from histone H3, which can be used to identify substrates of histone methyltransferases (HMTs).

  • GC81876 structure
    GC81876Imlunestrant-d₄
    Purity: >98.00%

    Imlunestrant -d 4 (LY-3484356-d 4 ) is the deuterated-labeled Imlunestrant.

  • GC81879 structure
    GC81879NCP26 TFA
    Purity: >99.50%

    NCP26 TFA is an ATP-competitive ProRS inhibitor (with a K D of 271 nM in the absence of proline, and a K D of 0.35 nM in the presence of 100 μM proline).

  • GC81880 structure
    GC81880OSU-2S TFA
    Purity: >98.00%

    OSU-2S TFA is a non-immunosuppressive derivative of Fingolimod hydrochloride (FTY720).

  • GC81882 structure
    GC81882PROTAC CARM1 degrader-1 TFA
    Purity: >98.00%

    PROTAC CARM1 degrader-1 TFA is a highly selective CARM1 PROTAC degrader, with a DC 50 of 8.1 nM in MCF‑7 cells.

  • GC81883 structure
    GC81883(R)-AR/BRD4 RIPTAC-1
    CAS: 3083307-47-2
    Purity: >98.00%

    (R)-AR/BRD4 RIPTAC-1 is the R-enantiomer of AR/BRD4 RIPTAC-1.

  • GC81884 structure
    GC81884(R)-Vanzacaftor-d₄
    Purity: >98.00%

    (R)-Vanzacaftor -d 4 ((R)-VX-121-d 4 ) is the deuterated-labeled (R)-Vanzacaftor.

  • GC81886 structure
    GC81886(S)-Phenylpiracetam
    CAS: 949925-08-0
    Purity: >98.00%

    (S)-Phenylpiracetam ((S)-Carphedon; (S)-Fonturacetam; (S)-MRZ 9547) is an orally active and selective dopamine transporter inhibitor, with K i = 56 μM.

  • GC81890 structure
    GC81890Temozolomide-¹⁵N
    Purity: >98.00%

    Temozolomide - 15 N (NSC 362856- 15 N) is the 15 N-labeled Temozolomide.

  • GC81891 structure
    GC81891Tri-GalNAc-NH2
    CAS: 1646198-77-7
    Purity: >98.00%

    Tri-GalNAc-NH2 is a synthetic tri-N-acetylgalactosamine ligand that targets the asialoglycoprotein receptor (ASGPR).

  • GC81892 structure
    GC81892Vevorisertib tetrahydrochloride
    Purity: >98.00%

    Vevorisertib tetrahydrochloride (ARQ 751 tetrahydrochloride) is an orally active allosteric AKT inhibitor that blocks AKT phosphorylation.

  • GC81893 structure
    GC81893Rfamide TFA
    Purity: >99.50%

    Rfamide TFA (Arginylphenylalaninamide TFA) is a neuropeptide that has contraction-inducing activity in gastropod muscles.

  • GC81894 structure
    GC81894Adamantan-2-amine
    CAS: 13074-39-0
    Purity: >98.00%

    Adamantan-2-amine (2-Aminoadamantane) serves as the hydrophobic tag structural unit of Tubulin degrader 2 and is used for the synthesis of anticancer drugs that target tubulin via a dual mechanism.

  • GC81895 structure
    GC81895RB 101 hydrochloride
    Purity: >98.00%

    RB 101 hydrochloride is a blood-brain barrier-crossing prodrug as well as aminopeptidase N and neutral endopeptidase-24.11 inhibitor.

  • GC81897 structure
    GC81897HaloAUTAC tt15
    CAS: 2241668-45-9
    Purity: >96.00%

    HaloAUTAC tt15 is an autophagy-targeting chimera (AUTAC), that targets the Halo Tag carrying proteins, and degrades via the autophagy mechanism.

  • GC81898 structure
    GC81898LLC355
    Purity: >99.50%

    LLC355 is a discoidin domain receptor 1 ( DDR1 ) ATTEC degrader with a DC 50 of 150.8 nM.

  • GC81900 structure
    GC81900CP61 acetate
    Purity: >98.50%

    CP61 acetate is a CtBP1 and CtBP2 inhibitor that binds to dimeric CtBP1 and allosterically inhibits NADH binding, disrupting the NADH -dependent dimerization of CtBP1 and CtBP2, inducing aberrant mitosis and micronucleus formation, thereby inhibiting cell proliferation and colony formation.